Azapirones for generalized anxiety disorder

Cochrane Database of Systematic Reviews

Volumn 2006, Issue 3, 2006, Pages

  Chessick, Cheryl A ^a   Allen, Michael H ^a   Thase, Michael E ^b   Batista Miralha da Cunha, Angelo A B C ^c   Kapczinski, Flávio ^d   Silva de Lima, Mauricio ^e   dos Santos Souza, Juliano J S S ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; IPSAPIRONE; PYRIMIDINE DERIVATIVE;

ANXIETY DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; BUSPIRONE; HUMANS; PSYCHOTHERAPY; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33750099603     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006115     Document Type: Review

References (80)

1. Ansseau, M, Papart, P, Gérard, MA, Von Frenckell, R, Franck, G Controlled comparison of Buspirone and Oxazepam in Generalized Anxiety. Neuropsychobiology 1990-91;24:74-78.
2. Boerner R, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder-An 8-week randomized, double-blind multi-cenre clinical trial in 129 out-patients. Phytomedicine 2003;10(Supplement IV):38-49.
3. Bond AJ, Wingrove J, Curran HV, Lader MH. Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo. Journal of Affective Disorders 2002;72:267-271.
4. Boral GC, Bandopadhaya G, Ike VG, Jha RJ, Navani SR, Bowalekar SK, Raghu CN. Double-Blind, Randomized Clinical Evaluation of Buspirone and Diazepam in Generalized Anxiety Disorders. Advances In Therapy 1989;6(3):112-124.
5. Borison, RL, Albrecht, JW, Diamond, BI Efficacy and safety of a putative anxyiolitic agent: Ipsapirone. Psychopharmacology Bulletin 1990;6(26):207-209.
6. Boyer, WF, Feighner, JP A lacebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. International Clinical Psychopharmacology 1993;8:173-176.
7. Chiaie, RD, Pancheri, P, Casacchia, M, Stratta, P, Kotzalidis, GD, Zibellini, M Assessment of the efficacy of Buspirone in patients affected by generalized anxiety disorder, shifting to Buspirone from prior treatment with Lorazepam: a placebo-controlled, double blind study. Journal of Clinical Psychopharmacology 1995;15(1):12-19.
8. Cohn, JB, Wilcox, CS Low-sedation potential of Buspirone compared with Alprazolam and Lorazepam in the treatment of anxious patients: A double-blind study. The Journal of Clinical Psychiatry 1986;47(8):409-412.
9. Cohn J, Bowden C, Fisher J, Rodos J. Double-blind comparison of buspirone and clorazepate in anxious outpatients. American Journal of Medicine 1986;80(3B):10-16.
10. Cohn, J, Rickels, K A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Current Medical Research and Opinion 1989;11(5):304-320.
11. Cutler, NR, Sramek, JJ, Wardle, TS, Hesselink, JMK, Roeschen, JK The Safety and Efficacy of Ipsapirone vs. Lorazepam in outpatients with Gneralized Anxiety Disorder (GAD): Single Site Findings from a Multicenter Trial. Psychopharmacology Bulletin 1993;29(2):303-308.
12. Cutler, NR, Hesselinnk, JM, Sramek, JJ A phase II multicenter dose-finding, efficacy and safety trial of Ipsapirone in outpatients with generalized anxiety disorder. Progress in Neuro-psychopharmacology & Biological Psychiatry 1994;18:447-463.
13. Davidson, JRT, DuPont, RL, Hedges, D, Haskins, JT Efficacy, safety and tolerability of Venlafaxine Extended Release and Buspirone in outpatients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 1999;60(8):528-535.
14. DeMartinis, N, Runn, M, Rickels, K, mandos, L Prior Benzodiazepine Use and Buspirone Response in the Treatment of Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 2000;61(2):91-94.
15. Enkelmann, R Alprazolam versus Buspirone in the treatment of outpatients with Genralized Anxiety Disorder. Psychopharmacology 1991;105:428-432.
16. Fabre L. Double-Blind Comparison of Buspirone with Diazepam in Anxious Patients. Current Therapeutic Research, Clinical & Experimental 1987;41(5):751-758.
17. Feighner, JP, Merideth, CH, Gordon AH. A Double-Blind Comparison of Buspirone and Diazepam in Outpatients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 1982;43(12 [sec 2]):103-107.
18. Feighner, JP, Cohn, JB Analysis off Individual Symptoms in Generalized Anxiety - a Pooled, Multistudy, Double-Blind Evaluation of Buspirone. Neuropsychobiology 1989;21:124-130.
19. Fontaine R, Napoliellow MJ. Double-Blind Comparison of Buspirone 10 mg BID versus Buspirone 5mg TID in Generalized Anxiety Disorder. Current Therapeutic Research 1993;54(2):254-261.
20. Fresquet, A, Sust, M, Lloret, A, Murphy, MF, Carter, FJ, Campbell, GM, Marion-Landais, G Efficacy and safety of Lesopitron in Outpatients with Generalized Anxiety Disorder. The Annals of Pharmacotherapy 2000;34:147-153.
21. Harto, NE, Roland, J, Branconnier, MA, Spera, KF, Dessain, EC Clinical Profile of Gepirone, a Nonbenzodiazepine Anxiolytic. Psychopharmacology Bulletin 1988;24(1):154-160.
22. Jacobson, AF, Dominguez, RZ, Goldstein, BJ, Steinbook, RM Comparison of Buspirone and Diazepam in Generalized Anxiety Disorder. Pharmacotherapy 1985;5(5):290-296.
23. Laakmann, G, Schule, C, Lorkowski, G, Baghai, T Buspirone and Lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 1998;136:357-366.
24. Lader, M, Scotto, JC A multicentre double-blind comparison of hydroxizine, buspirone and placebo in patients with GAD. Psychopharmacology 1998;139:402-406.
25. Lemoine P, Rouillon F, Pouget D. Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders [Efficacite et sevrage du clobazam comparativement au lorazepam et a la buspirone dans le traitement du trouble anxiete generalisee]. Encephale 1996;22(6):461-7.
26. Majercsik E, Haller J, Leveleki C, Baranyi J, Halasz J, Rodgers R. The effect of social factors on the axiolytic efficacy of buspirone in male rats, male mice, and men. Prgress in Neuro-Psychopharmacology & Biological Psychiatry 2003;27:1187-1199.
27. Murphy S, Owen R, Tyrer P. Comparative Assessment of Efficacy and Withdrawal symptoms After 6 ad 12 Weeks' Treatment with Diazepam or Buspirone. British Journal of Psychiatry 1989;154:529-534.
28. Pecknold, JC, Familamiri, P, Chang, H, Wilson, R, Alarcia, J, McClure, J Buspirone: Anxiolytic?. Progress in Neuro-psychopharmacology & Biological Psychiatry 1985;9:638-642.
29. Pecknold, JC, Matas, M, Howarth, BG, Ross, C, Swinson, R, Vezeau, C, Ungar, W Evaluation of Buspirone as an antianxiety agent: Buspirona and Diazepam versus Placebo. Canadian Journal of Psychiatry 1989;34:766-771.
30. Pollack, MH, Worthington, JJ, Manfro, GG, Otto, MW, Zucker, BG Abecarnil for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Comparison of Two Dosage Ranges of Abecarnil and Buspirone. The Journal of Clinical Psychiatry 1997;58(suppl 11):19-23.
31. Ramchandran, V, Thirunavukarasu, M, Oke, VG, Jha, J, Navani, SR, Bowalekar, SK, Raghu, SN Comparative Clinical Evaluation of Buspirone and Diazepam in Generalized Anxiety Disorder. Current Therapeutic Research 1990;47(3):502-510.
32. Rickels, K, Schweizer, E, DeMartinis, N, Mandos, L, Mercer, C [Gepirone and Diazepam in Generalized Anxiety Disorder: A Placebo-Controlled Trial]. Journal of Clinical Psychopharmacology 1997;17(4):272-277.
33. Ross, CA, Matas, M A Clinical Trial of Buspirone and Diazepam in the Treatment of Generalized Anxiety Disorder. Canandian Journal of Psychiatry 1987;32:351-355.
34. Sacchetti E, Zerbini O, Banfi F. Tansella M. Overlap of Buspirone with Lorazepam, Diazepam and Bromazepam in Patients with Generalized Anxiety Disorder: Findings from a Controlled, Multicentre, Double-Blind Study. Human Psychopharmacology 1994;9:409-422.
35. Sramek JJ, Tansma M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR. Efficacy of Buspirone in Generalized Anxiety Disorder with Coexisting Mild Depressive Symptoms. The Journal of Clinical Psychiatry 1996;57:287-291.
36. Sramek JJ, Frackiewicz EJ, Cutler NR. Efficacy and Safety of Two Dosing Regimens of Buspirone in the Treatment of Outpatients with Persistent Anxiety. Clinical Therapeutics 1997;19(3):498-506.
37. Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1995;19:567-575.
38. Bouvard M. Buspirone in Adolescents with Anxiety Disorders. American Psychiatric Association, Annual Meeting. 1998.
39. Caetano D, Oliveira J. Double blind comparative study between bsupirone and lorazepam in the treatment of generalized anxiety. Jornal Brasileiro de Psiquiatria 1990;39(1):43-46.
40. Costa e Silva J, Ruschel S. A double-blind comparison between buspirone vs bromazepm in outpatients with symptoms of anxiety. Jornal Brasileiro de Psiquiatria 1987;36(4):253-8.
41. Fontaine, R, Reaudry, P, Beauclair, L, Chouinard, G Comparison of withdrawal of Buspirone and Diazepam: A placebo-controlled study. Progress in Neuro-Psychopharmacol & Biological Psychiatry 1987;11:189-197.
42. Goldberg, HL, Finnerty, R Comparison of Buspirone in Two Separate Studies. The Journal of Clinical Psychaitry 1982;43(12[sec 2]):87-92.
43. Lucki I, Rickels K, Giesecke M, Geller A. Differential effects of the anxiolytic drugs, diazepam and buspirone, on memory function. British Journal of Clinical Pharmacology 1987;23(2):207-11.
44. Olajide, D, Lader, M A Comparison of Buspirone, Diazepam and Placebo in Patients with Chronic Anxiety States. Journal of Clinical Psychopharmacology 1987;7(3):148-152.
45. Petracca, A, Nisita, C, McNair, D, Melis, GB, Guerani, G, Cassano, GB Treatment of Generalized Anxiety Disorder: Preliminary Clinical Experience With Buspirone. The Journal of Clinical Psychiatry 1990;51(9 [suppl]):31-39.
46. Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. Journal of Clinical Psychiatry 1982;43(12 Pt 2):81-6.
47. Rickels K, Schweizer E, Csanalosi I, Case W, Chung H. Long-term Treatment of Anxiety and Risk of Withdrawal. Archives of General Psychiatry 1988;45(5):444-450.
48. Rickels, K, DeMartinis, N, Garcia-España, F, Greeblatt, DJ, Mandos, LA, Rynn, M Imipramine and Buspirone in Treatment of Patients With Generalized Anxiety Disorder Who are Discontinuing Long-Term Benzodiazepine Therapy. The American Journal of Psychiatry 2000;157(12):1973-1979.
49. Rolland P, Kablinger A, Brannon G, Freeman A. Treatment of Generalised Anxiety Disorder with Venlafaxine XR. Clinical Drug Investigation 2000;19(2):163-165.
50. Rouillon F. A double-blind controlled study of PCR 7060 vs buspirone in the treatment of generalised anxiety disorder. European Neuropsychopharmacology 1995;5(3):367.
51. Schweizer E, Rickels K, Csanalosi I, London J, Turner D. A Placebo-Conrolled Study of Enciprazine in the Treatment of Generalized Anxiety Disorder: A Preliminary Report. Psychopharmacology Bulletin 1990;26(2):215-217.
52. Shah, AV, Parulkar, GB, Mattoo, V, Bowalekar, SK, Raghu, CN Clinical evaluation of Buspirone and Diazepam in Generalized Anxiety Disorders. Current Therapeutic Research 1991;50(6):827-834.
53. Shen J, Zhong X. Clinical study on buspirone hydrochloride treated for generalized anxiety disorder. Journal of Chinese Civil Administration Medicine 1999;11(2):70-2.
54. Sontheimer DL, Ables AZ. Is Imipramine or Buspirone Treatment Effective in Patients Wishing to Discontinue Long-Term Benzodiazepine Use?. Family Practice 2001;50(3):203.
55. Sramek, JJ, Fresquet A, Gaston M-L, Hourani J, Jhee SS, Martinez L, Jensen C, Bolles K, Carrington A, Cutler N. Establishing the Maximum Tolerated Dose of Lesopitron in Patients With Generalized Anxiety Disorder: A Bridging Study. Journal of Clinical Psychopharmacology 1996;16(6):454-458.
56. Strand, M, Hetta, J, Rosen, A, Sorensen, S, Malmstrom, R, Fabian, C, Marits, K, Vetterskog, K, Liljestrand, AG, Hegen, C A Double-Blind Controlled Trial in Primary Care Patients With Generalized Anxiety: A Comparison Between Buspirone and Oxazepam. The Journal of Clinical Psychiatry 1990;51(9 [suppl]):40-45.
57. Tollefson, GD, Lancaster, SP, Montague-Clouse, J The Association of Buspirone ands Its Metabolite 1-pyrimidinylpiperazine in the Remission of Comorbid Anxiety with Depressive Features and Alcohol Dependency. Psychopharmacology Bulletin 1991;27(2):163-170.
58. Tyrer P, Owen R. Anxiety in primary care: is short-term drug treatment appropriate?. Journal of Psychiatric Research 1984;18(1):73-8.
59. van Amerongen A, Viel J, Konopka C, Berdeaux G. French multicenter dose-ranging trial of ipsapirone in GAD patients: a randomized, double-blind parallel group placebo-controlled trial. 5th World Congress of Biological Psychiatry. Florence, 9-14 June, 1991.
60. van Laar M, Volkerts E, van Willigenburg A. Therapeutic efects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. Journal of Clinical Psychopharmacology 1992;12(2):86-95.
61. Wheatley, D Buspirone: Multicenter Efficacy Study. The Journal of Clinical Psychiatry 1982;43(12[sec 2]):92-94.
62. Yevich JP, Eison MD, Eison AS, Taylor DP, Yocca FD, VanderMaelen CP, Riblet LA, Robinson DS, Roberts Dl, Temple DL. Gepirone hydrochloride: preclinical pharmacology and recent clinical findings. Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy 1990;361:443-51.
63. Altman DG, Bland JM. Detecting skeweness fromsummary information. British Medical Journal 1996;313(7066):1200.
64. Ballenger, JC, Davidson, JRT, Lecrubier, Y, Nutt, DJ, Borkovec, T, Rickels K, Stein, D, Wittchen, H Consensus statement on Generalized Anxiety Disorder from the Tenth Internation Consensus Group on Depression and Anxiety. The Journal of Clinical Psychiatry 2001;62(suppl 11):53-58.
65. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder. Journal Consulting and Clinical psychology 1993;61:611-19.
66. Brawman-Mintzer O. Pharmacological treatment of Generalized Anxiety Disorder. The Psychiatric Clinics of North America 2001;24(1):119-137.
67. Bruce SE, Yonker KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keler MB. Influence of Psychiatric Comorbidity on Recovery and Recurrence in Generalized Anxiety Disorder, Social Phobia, and Panic Disorder: A 12-Year Prospective Study. American Journal of Psychiatry 2005;162:1179-1187.
68. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold Jc, Smith Wt, Rickels K. Use of buspirone in patients with generalized anxiety disorde and coexising depressive symtoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992;24(4):193-201.
69. Goa KL, Ward A 32. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs (New Zealand) 1986;2:114-129.
70. Hamilton, M The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-55.
71. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intrventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd.
72. Kapczinski F, Lima MS, Souza S, Cunha A, Schmitt R. Antidepressants for generalized anxiety disorder (Review). The Cochrane Collaboration 2005.
73. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorers in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 1994;51:8-19.
74. Lydiard, RB, Ballenger, JC, Rickels, K A Double-Blind Evaluation of the Safety and Efficacy of Abecarnil, Alprazolam and Placebo in Outopatients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 1997;58(suppl 11):11-18.
75. Mandos LA, Rickels K, Cutler N, Roeschen J, Keppel Hesselink JM, Schweizer E. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. International Clinical Psychopharmacology 1995;10:251-256.
76. Meoni P: Salina E, Yves B, Hackett D. Pattern of Symptom Improvement Following Treatment with Venlafaxine XR in Patients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 2001;62(11):888-893.
77. Pittler MH, Ernst E. Kava extract for treating anxiety (Cochrane Review). Cochrane Database Systematic Review 2001, Issue 4. [: CD003383]
78. Shader, RI, Greenblatt, DJ Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 1993;328:1398-1405.
79. Wingerson D, Nguyen C, Roy-Byrne PP. Chlomipramine treatment for Generalized Anxiety Disorder [Journal of Clinical Psychopharmacology]. 1992; Vol. 12, issue 3:214-215.
80. Wittchen, HU, Zhao, S, Kessler, RC, Eaton, WW DSM III-R generalized anxiety disorder in the national comorbidity survey. Archives of General Psychiatry 1994;51:355-364.